ReviewScientific reports2013
Diagnostic and therapeutic strategy and the most efficient prognostic factors of breast malignant fibrous histiocytoma.
Review in Scientific reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Undifferentiated Pleomorphic Sarcoma of the Breast: A Case Report and Literature Review.Cureus · 2026Article
- Multimodal nomogram for predicting axillary pathological complete response after neoadjuvant therapy in clinically node-positive breast cancer.Frontiers in oncology · 2026Article
- Identifying low-risk breast cancer patients for axillary biopsy exemption: a multimodal preoperative predictive model.European journal of medical research · 2025Article
- Article
- Primary Breast Sarcoma: A Two-Centre Analysis and Review of Literature.Breast care (Basel, Switzerland) · 2023Article
- Analysis of prognostic factors of undifferentiated pleomorphic sarcoma and construction and validation of a prediction nomogram based on SEER database.European journal of medical research · 2022Article
- Primary giant cell malignant fibrous histiocytoma of the lung: a rare case report and literature review.Translational cancer research · 2020Article
- Radiation-induced undifferentiated pleomorphic sarcoma of the breast.BMJ case reports · 2020Article
- The Role of Adjuvant Radiotherapy for a Case of Primary Breast Sarcoma: A Plan Comparison between Three Modern Techniques and a Review of the Literature.Case reports in medicine · 2018Article
- A nomogram to predict the probability of axillary lymph node metastasis in early breast cancer patients with positive axillary ultrasound.Scientific reports · 2016Article
- Hexokinase and phosphofructokinase activity and intracellular distribution correlate with aggressiveness and invasiveness of human breast carcinoma.Oncotarget · 2015Article
- Malignant fibrous histiocytoma of visceral organs: clinicopathologic features and diagnostic value of ezrin and HMG-CoA reductase.International journal of clinical and experimental pathology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We analyzed the clinicopathological features of 9 breast malignant fibrous histiocytoma (MFH) patients. Immunohistochemistry was used to make both diagnosis and differential diagnosis, and to identify prognostic factors. All tumors lacked epithelial markers but expressed mesenchymal markers, suggesting a mesenchymal origin. Of the five cases expressing Ki-67, two of three patients with axillary lymph node involvement died between 6-8 months, and two died at 17 and 26 months after diagnosis. The two remaining cases, with low Ki-67 expression, had no recurrent or metastatic disease at 145 months after diagnosis. Previous studies have shown that surgery is the primary treatment of choice, but no clear benefit from adjuvant chemotherapy was observed. We demonstrate that axillary lymph node involvement and high expression of Ki-67 are associated with poorer prognosis. A literature review indicates surgery remains the first choice for MFH, but benefits from adjuvant chemotherapy remain unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.